Biotek-snakken — December 2021
-
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference call and webcast today at 8:00 a.m. ET/5:00 a.m. PT REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power
Yahoo Finance (finance.yahoo.com)
-
Ser da også lidt tyndt ud på overfladen 1 PR 12 SD på 40n. Ser ud som om der er muligheder i Colorectal. side 12+20 i slide. Absolut ingen/lille virkning i GEA, så måske Zyme har ret i at deres tal er super gode. https://investors.boltbio.com/static-files/76e91664-ddf5-4d7f-814e-49821756b540
-
He rkommer lige et link til den seneste melding: https://via.ritzau.dk/ir-files/13559605/4520/5869/20211206 -ViroGates Company ann. 23.pdf
-
-
-
Er også forholdsvist tungt lastet i både Adicet og Lava. Og jeg synes egentlig, at det var rigtig flotte, omend meget tidlige, data som Adicet kunne præsentere, som lover virkelig godt for gamma delta.
nogen der er med i Dare de fik godkendelse i aftes og var børs stoppet hele aften nogen der har en mening om udsigterne for aktien / kursen Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind